Brainstorm Cell Therapeutics (NASDAQ:BCLI) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLIFree Report) in a research report sent to investors on Tuesday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Trading Up 6.1 %

NASDAQ BCLI opened at $0.47 on Tuesday. The company’s fifty day simple moving average is $0.51 and its 200-day simple moving average is $0.40. The stock has a market cap of $32.94 million, a P/E ratio of -1.38 and a beta of 0.43. Brainstorm Cell Therapeutics has a 52 week low of $0.13 and a 52 week high of $2.82.

Brainstorm Cell Therapeutics (NASDAQ:BCLIGet Free Report) last issued its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.02. On average, research analysts expect that Brainstorm Cell Therapeutics will post -0.28 EPS for the current fiscal year.

Institutional Trading of Brainstorm Cell Therapeutics

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC purchased a new position in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLIFree Report) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned about 0.12% of Brainstorm Cell Therapeutics at the end of the most recent quarter. 14.33% of the stock is currently owned by institutional investors.

About Brainstorm Cell Therapeutics

(Get Free Report)

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.

Read More

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.